Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermapharm Holding SECHIX:DMPD 80 Days Sales Outstanding is 36.63 as of Mar. 2026, which is 50% above its 10-year median of 24.39. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €44.05. The stock has 5 warning signs investors should review. Among 949 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 83.77% on this metric.
The historical rank and industry rank for Dermapharm Holding SE's Days Sales Outstanding or its related term are showing as below:
CHIX:DMPd'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.95 Med: 24.39 Max: 38.88
Current: 38.88
During the past 13 years, Dermapharm Holding SE's highest Days Sales Outstanding was 38.88. The lowest was 17.95. And the median was 24.39.
CHIX:DMPd's Days Sales Outstanding is ranked better than 83.77% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72.18
vs CHIX:DMPd: 38.88
Dermapharm Holding SE's Days Sales Outstanding
increased
from Mar. 2025 (34.75) to Mar. 2026 (36.63).
Dermapharm Holding SE (CHIX:DMPd) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Dermapharm Holding SE Days Sales Outstanding Related Terms
Dermapharm Holding SE Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE Days Sales Outstanding Chart
CHIX:DMPD vs ZTS, UTHR: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Days Sales Outstanding falls into.
Dermapharm Holding SE Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (CHIX:DMPD) has a Days Sales Outstanding of 36.63 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Dermapharm Holding SE and its competitors. This is 50% above median its historical median of 24.39. Over the past decade, Dermapharm Holding SE's Days Sales Outstanding has ranged from 17.95 to 38.88. According to the industry distribution chart, Dermapharm Holding SE ranks #154 out of 949 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Dermapharm Holding SE's Days Sales Outstanding too high?
Dermapharm Holding SE's current Days Sales Outstanding of 36.63 is 50% above median its 10-year median of 24.39. Over the past 10 years, this metric has ranged from a low of 17.95 to a high of 38.88. The Drug Manufacturers industry median Days Sales Outstanding is 72.18. Dermapharm Holding SE's value of 36.63 is 49.3% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #154 out of 949 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #154 out of 949 companies for Days Sales Outstanding. This places Dermapharm Holding SE in the top 16% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 72.18. Dermapharm Holding SE's value of 36.63 is 49.3% below this benchmark. Historically, Dermapharm Holding SE's own Days Sales Outstanding has ranged from 17.95 to 38.88 over the past decade. While the company's 10-year median is 24.39 vs. the industry median of 72.18, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.18, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current Days Sales Outstanding of 36.63 is 49.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Days Sales Outstanding is 36.63, which is 50% above median its own 10-year median of 24.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Days Sales Outstanding of 36.63. The stock's GF Value™ is €44.05, compared to a current price of €46.18 — trading 4.8% above its estimated fair value. The current Days Sales Outstanding is 36.63, which is 50% above median its 10-year median of 24.39 and 49.3% below the Drug Manufacturers industry median of 72.18. Dermapharm Holding SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Days Sales Outstanding is 36.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 4.8% above its estimated GF Value™ of €44.05.
Key valuation signals for CHIX:DMPD:
Days Sales Outstanding: 36.63 (50% above median its 10-year median of 24.39)
GF Value™: €44.05 vs. price of €46.18 (4.8% above fair value)
Industry Position: 49.3% below the Drug Manufacturers median (#154 of 949)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
